1-9 of 9
William E. Pierceall, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Michael Amatangelo, Oliver Van Oekelen, MD MSc, Adeeb H Rahman, PhD, Alessandro Lagana, PhD, Sarah Gooding, FRCPath,MRCP,MBBChir, Hervé Avet-Loiseau, MD PhD, Udo Oppermann, PhD, William E Pierceall, PhD, Anjan Thakurta, Samir Parekh, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1775.
https://doi.org/10.1182/blood-2019-126146
Published: 2019
Journal Articles

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

James Croft, MBBS, BSc, Andrew Hall, Amy L Sherborne, PhD, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Louise Flanagan, PhD, Mamta Garg, MD FRCP, FRCPath, Suzana Couto, Maria Wang, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, William E Pierceall, PhD, Anjan Thakurta, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser
Journal: Blood
Blood (2019) 134 (Supplement_1): 4327.
https://doi.org/10.1182/blood-2019-123640
Published: 2019
Journal Articles

Clinical BET Inhibitor RG6146 Demonstrates Potent and on-Target Activity in Pre-Clinical Models of Hematological Malignancy and Combines with Anti-CD20 and BCL-2 Inhibition to Provide Superior Efficacy

Astrid Rueflibrasse, PhD, Thomas Friess, PhD, Stephanie Lechner, Lisa Wellinger, Jurriaan Brouwer, William E. Pierceall, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2071.
https://doi.org/10.1182/blood.V130.Suppl_1.2071.2071
Published: 2017
Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD
Journal: Blood
Blood (2016) 128 (22): 2843.
https://doi.org/10.1182/blood.V128.22.2843.2843
Published: 2016
Journal Articles

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Bernhard Reis, PhD, Lori Jukofsky, Gong Chen, PhD, Giovanni Martinelli, Hua Zhong, PhD, Venus So, PhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Mark W. Drummond, PhDMD, Sarit E. Assouline, MDMSc, Maneja Hashemyan, Michel Theron, PhD, Steven Blotner, PhD, Je-Hwan Lee, MD PhD, Margaret Kasner, MD, Sung-Soo Yoon, Ruediger Rueger, MD, Karen Seiter, MD, Steven Middleton, PhD, Kevin R. Kelly, MD, PhD, Norbert Vey, Karen W.L. Yee, MD, Gwen Nichols, MD, Lin-Chi Chen, MD PhD, William E. Pierceall, PhD
Journal: Blood
Blood (2015) 126 (23): 2580.
https://doi.org/10.1182/blood.V126.23.2580.2580
Published: 2015
Journal Articles

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Karen Yee, MD, Giovanni Martinelli, MD, Norbert Vey, MDPhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Karen Seiter, MD, Sarit Assouline, MD MSc, Mark Drummond, MD PhD, Sung-Soo Yoon, MDPhD, Margaret Kasner, MD, Je-Hwan Lee, MD PhD, Kevin R. Kelly, MD PhD, Steven Blotner, PhD, Brian Higgins, Steven Middleton, PhD, Gwen Nichols, MD, Gong Chen, PhD, Hua Zhong, PhD, William E. Pierceall, PhD, Jianguo Zhi, PhD, Lin-Chi Chen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 116.
https://doi.org/10.1182/blood.V124.21.116.116
Published: 2014
Journal Articles

Mcl-1 Dependence Predicts Response To Vorinostat and Gemtuzumab Ozogamicin In Acute Myeloid Leukemia

William E. Pierceall, PhD, Ryan Lena, BS, Bruno C. Medeiros, MD, Elihu H. Estey, MD, Noel Blake, B.S., Michael Elaschoff, Ph.D., Michael Cardone, PhD, Roland B. Walter, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1305.
https://doi.org/10.1182/blood.V122.21.1305.1305
Published: 2013
Journal Articles

BH3 Profiling As Predictor Of 5-Azacytidine and Decitabine Clinical Responses

Raoul Tibes, MD, PhD, Steven M. Kornblau, MD, William E. Pierceall, PhD, Ryan Lena, BS, Yi Hua Qiu, MD, Michael Cardone, PhD, Leena Chaudhuri, PhD, Veena Fauble, MD, Michael Elashoff, Noel Blake, B.S., Ruben A. Mesa, MD, James M Bogenberger, PhD
Journal: Blood
Blood (2013) 122 (21): 603.
https://doi.org/10.1182/blood.V122.21.603.603
Published: 2013
Journal Articles

BH3 Profiling Predicts 5-Azacytidine Response in Malignant Myeloid Cells

James M Bogenberger, PhD, William E. Pierceall, PhD, Ryan Lena, BS, Reinhold Munker, MD, Kaoru Tohyama, MD, PhD, Lisa Sproat, MD, MSW, Pierre Noel, MD, Jose F. Leis, MD, PhD, James L Slack, MD, Ruben A. Mesa, Michael Cardone, PhD, Raoul Tibes, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1432.
https://doi.org/10.1182/blood.V120.21.1432.1432
Published: 2012